Recordati S.p.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Koremans
- Full Time Employees
- 4,693
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Via Matteo Civitali,1 Milan MI Italy 20148
- IPO Date
- Jan 1, 1984
- Website
- recordati.com
- Similar Companies
- Business
- Recordati Industria Chimica e Farmaceutica S.p.A. researches, develops, manufactures and markets pharmaceuticals worldwide, operating through Specialty and Primary Care, and Rare Diseases segments. The company offers a broad portfolio of proprietary and licensed products across therapeutic areas including cardiovascular disorders such as hypertension, angina pectoris and cardiac rhythm disorders with flagship brands Zanidip (lercanidipine, a calcium-channel blocker), Avodart/Combodart/Duodart (dutasteride) and Vazkepa (icosapent ethyl); urogenital treatments for benign prostatic hyperplasia and lower urinary tract symptoms; central nervous system therapies including Reaglia for schizophrenia; anti-infectives such as antibiotics, antivirals, Lomexin for gynecological and dermatological infections and Hexaspray throat spray; gastroenterology products; pain management; dermatologicals; obstetrics and gynecology; over-the-counter pharmaceuticals; consumer healthcare and dietary supplements via Natural Point srl including Magnesio Supremo; and rare disease treatments such as Isturisa (pasireotide) for Cushing's syndrome, Cystadrops for cystinosis, Eligard for hormone-dependent prostate cancer, Sylvant for oncology indications, and pipeline candidates REC 0559 for neurotrophic keratitis and REC 0545 for maple syrup urine disease. Founded in 1926 as Laboratorio Farmacologico Reggiano by Giovanni Recordati in Correggio, Italy, and headquartered in Milan following the 1953 headquarters transfer, the company employs around 4,580 people and maintains operations in approximately 150 countries across Europe, Russia, CIS countries, Ukraine, Turkey, North Africa, US, Canada, Mexico, South America, Japan, Australia and other regions through subsidiaries including Recordati Rare Diseases, Casen Recordati, Jaba Recordati, Recordati Ilaç, Opalia Recordati, Italchimici, Recordati AG and others. Recent developments include the October 2024 agreement with Sanofi to acquire global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease, for an upfront US$825 million plus up to US$250 million in milestones, expected to close by year-end and immediately accretive to EBITDA; a license and supply agreement with Amarin to commercialize Vazkepa strengthening its cardiovascular franchise; ongoing expansion of its rare diseases portfolio into endocrinology and oncology; and prior acquisitions such as EUSA Pharma, Tonipharm, Natural Point, Pro Farma AG and Italchimici to bolster specialty, primary care and OTC offerings.
Company News
RECORDATI ANNOUNCES THE WINNER OF THE 12TH EDITION OF THE ARRIGO RECORDATI PRIZE FOR SCIENTIFIC RESEARCH
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
RECORDATI: PROSEGUE IL SOLIDO SLANCIO DI CRESCITA DEL GRUPPO NEL PRIMO SEMESTRE DEL 2026 RICAVI NETTI +6,6%, EBITDA +8,8%, UTILE NETTO RETTIFICATO +6,7%
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%
RECORDATI: IL FORTE SLANCIO DEL GRUPPO PROSEGUE NEL PRIMO TRIMESTRE DEL 2026 RICAVI NETTI +4,9%, EBITDA(1) +5,0%, UTILE NETTO RETTIFICATO(2) +7,2%
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION